Goldman Sachs Alternatives buys control of Italian medtech firm Numantec

• Numantec supplies healthcare products and drug-delivery devices, operating seven manufacturing facilities across Europe and the U.S. with approximately 600 employees
• The deal values Numantec at approximately €700 million, though official financial terms were not disclosed by the companies
• Under Goldman Sachs ownership, Numantec is expected to continue European expansion and strengthen its U.S. presence following its 2023 acquisition of rival Health Line International

Goldman Sachs Alternatives Acquires Italian Medtech Firm Numantec

Goldman Sachs' private equity arm has agreed to acquire a controlling stake in Italian medical equipment manufacturer Numantec from White Bridge Investment, with the transaction valued at approximately €700 million according to a source familiar with the matter. The deal is expected to close in Q4.

Company Profile:

Numantec, based near Mantua in northern Italy, specializes in healthcare products and drug-delivery devices. The company employs approximately 600 people and operates seven manufacturing facilities across Europe and the United States.

Strategic Background:

White Bridge Investment built Numantec through multiple acquisitions following its 2021 investment in Delta Med, an Italian manufacturer of vascular access devices. The company expanded into the U.S. market in 2022 with the acquisition of Health Line International.

Growth Strategy:

Under Goldman Sachs ownership, Numantec is expected to continue its European expansion while strengthening its U.S. market presence. Goldman Sachs cited the appeal of the company's steady revenues amid macroeconomic uncertainty as a key driver for the investment.

Transaction Advisors:

JPMorgan served as financial adviser to White Bridge Investment, while Goldman Sachs International advised Goldman Sachs Alternatives on the acquisition.

Market Implications:

The deal reflects continued private equity interest in the resilient medtech sector, particularly companies with diversified geographic operations and stable cash flows. The transaction underscores the attractiveness of defensive healthcare assets during periods of economic volatility, with Goldman Sachs betting on consistent demand for medical devices and drug-delivery systems.